v3.25.1
Revenues
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
March 31,
20252024
Xywav$344,804 $315,300 
Xyrem37,241 64,232 
Epidiolex/Epidyolex217,737 198,716 
Sativex5,407 2,735 
Total Neuroscience605,189 580,983 
Rylaze/Enrylaze94,233 102,750 
Zepzelca63,033 75,100 
Defitelio/defibrotide 40,662 47,676 
Vyxeos29,544 32,023 
Ziihera1,975 — 
Total Oncology229,447 257,549 
Other4,782 3,570 
Product sales, net839,418 842,102 
High-sodium oxybate AG royalty revenue48,946 49,947 
Other royalty and contract revenues9,477 9,934 
Total revenues$897,841 $901,983 

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
March 31,
20252024
United States$797,945 $808,214 
Europe83,607 71,355 
All other16,289 22,414 
Total revenues$897,841 $901,983 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
March 31,
20252024
ESSDS42 %42 %
ASD12 %6 %
McKesson11 %12 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days.